About Neomend
Neomend is a company based in Irvine (United States) founded in 1999 was acquired by CR Bard in October 2012. Neomend has raised $38.83 million across 3 funding rounds from investors including Blackstone, CR Bard and Sanderling Ventures. Neomend operates in a competitive market with competitors including Cohera Medical, GATT Technologies BV, Sealonix, OptMed and BORAYER, among others.
- Headquarter Irvine, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Neomend Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$38.83 M (USD)
in 3 rounds
-
Latest Funding Round
$33.12 M (USD), Series D
Feb 04, 2010
-
Investors
Blackstone
& 5 more
-
Employee Count
Employee Count
-
Acquired by
CR Bard
(Oct 23, 2012)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Neomend
Neomend has successfully raised a total of $38.83M across 3 strategic funding rounds. The most recent funding activity was a Series D round of $33.12 million completed in February 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series D — $33.1M
-
First Round
First Round
(14 May 2009)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2010 | Amount | Series D - Neomend | Valuation | Sanderling Ventures , Prospect Venture Partners |
|
| Sep, 2009 | Amount | Unspecified - Neomend | Valuation |
investors |
|
| May, 2009 | Amount | Unspecified - Neomend | Valuation |
investors |
|
Investors in Neomend
Neomend has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Blackstone, CR Bard and Sanderling Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biomedical investment financing and active management services.
|
Founded Year | Domain | Location | |
|
Investments are made in US life sciences and healthtech firms.
|
Founded Year | Domain | Location | |
|
Diversified investment management is provided across multiple asset classes.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Neomend
Financial Statements - Neomend
Neomend Comparisons
Competitors of Neomend
Neomend operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cohera Medical, GATT Technologies BV, Sealonix, OptMed and BORAYER, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Develops innovative surgical adhesives and sealants for medical use.
|
|
| domain | founded_year | HQ Location |
Polymer-based adhesive tissue tape is developed for surgical sealants.
|
|
| domain | founded_year | HQ Location |
Developer of hemostatic sealants for surgeries
|
|
| domain | founded_year | HQ Location |
Biocompatible polymers and genitourinary therapeutics are developed and commercialized.
|
|
| domain | founded_year | HQ Location |
Biomaterials for surgery and wound repair are developed.
|
Frequently Asked Questions about Neomend
Neomend was founded in 1999 and raised its 1st funding round 10 years after it was founded.
Neomend is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Neomend is a funded company, having raised a total of $38.83M across 3 funding rounds to date. The company's 1st funding round was a Unspecified of $2.7M, raised on May 14, 2009.
Provider of air leak sealant for thoracic surgery. By using the proprietary Hydrogel technology platform the company has developed advanced wound care products for a variety of applications, including wound healing, prevention of post-surgical adhesions, and site-specific, sustained drug delivery. The lead product is Progel Pleural Air Leak Sealant, for lung surgery.
Neomend's top competitors include OptMed, GATT Technologies BV and Sealonix.
Neomend has 6 investors. Key investors include Blackstone, CR Bard, Sanderling Ventures, Prospect Venture Partners, and Vivo Capital.